- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of daclatasvir in hepatitis C virus
Authors
Keywords
-
Journal
Expert Review of Anti-Infective Therapy
Volume 12, Issue 9, Pages 1025-1031
Publisher
Informa UK Limited
Online
2014-07-25
DOI
10.1586/14787210.2014.942282
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection
- (2014) Hiromitsu Kumada et al. HEPATOLOGY
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
- (2014) Mark S. Sulkowski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatitis C virus NS5A inhibitors and drug resistance mutations
- (2014) Shingo Nakamoto WORLD JOURNAL OF GASTROENTEROLOGY
- Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection
- (2013) Gregory T. Everson et al. GASTROENTEROLOGY
- Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir
- (2013) Fiona McPhee et al. HEPATOLOGY
- 1418 DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY
- (2013) G.J. Dore et al. JOURNAL OF HEPATOLOGY
- Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
- (2013) Anna S. Lok et al. JOURNAL OF HEPATOLOGY
- Antiviral activity and resistance of HCV NS5A replication complex inhibitors
- (2013) Min Gao Current Opinion in Virology
- Hepatitis C Virus RNA Elimination and Development of Resistance in Replicon Cells Treated with BMS-790052
- (2012) Chunfu Wang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b
- (2012) Fumitaka Suzuki et al. JOURNAL OF CLINICAL VIROLOGY
- Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir
- (2012) Yoshiyasu Karino et al. JOURNAL OF HEPATOLOGY
- Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
- (2012) Yoshiyuki Suzuki et al. JOURNAL OF HEPATOLOGY
- Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1
- (2012) Norio Akuta et al. JOURNAL OF MEDICAL VIROLOGY
- Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
- (2011) Richard E. Nettles et al. HEPATOLOGY
- Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders
- (2011) Kazuaki Chayama et al. HEPATOLOGY
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection
- (2011) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatic ISG Expression Is Associated With Genetic Variation in Interleukin 28B and the Outcome of IFN Therapy for Chronic Hepatitis C
- (2010) Masao Honda et al. GASTROENTEROLOGY
- Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009)
- (2010) Izumi Namiki et al. HEPATOLOGY RESEARCH
- Diagnosis, management, and treatment of hepatitis C: An update
- (2008) Marc G. Ghany et al. HEPATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now